SLC26A4 and neoplasm: miR-3174, recognized as a candidate for tumor therapy, has exhibited aberrant expression in glioblastoma, endometrial cancer, and bladder cancer.25-27 Wang and colleagues confirmed that miR-3174 was upregulated in hepatocellular carcinoma, highlighting its role in mediating cell activities by binding to FOXO1.15 In this study, miR-3174 was assessed to be elevated in plasma and cells of rectal cancer compared to the healthy group and negatively regulated by SLC26A4-AS1.